Every 10-Q that Cue Biopharma Inc (CUE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CUE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CUE filings page.
Cue Biopharma, Inc., a clinical-stage biopharma company, reported a sharply higher net loss while executing major licensing and financing transactions for the quarter and six months ended June 30, 2026. Collaboration revenue rose to $7.9 million for the quarter and $13.6 million year-to-date, compared with $3.0 million and $3.4 million in the prior-year periods, reflecting increased partner activity.
Operating expenses expanded substantially, with general and administrative at $46.6 million and research and development at $49.0 million in the quarter, driven by a $35.1 million upfront license cost for the Ascendant anti-IgE program (CUE-221), elevated stock-based compensation of $23.8 million in the quarter, and other one-time items. A $90.0 million loss on issuance of liability-classified warrants, partly offset by a $24.5 million fair value gain, led to a quarterly net loss of $153.1 million and a six-month loss of $158.2 million.
Cash and cash equivalents were $17.4 million at June 30, 2026, with total assets of $30.7 million and stockholders’ equity of $2.3 million. A July 2026 private placement added approximately $49.8 million of net proceeds, which, together with existing cash, is expected to fund operations for at least 12 months from issuance. A 1-for-30 reverse stock split was effected in April 2026, reducing shares outstanding but increasing the number of authorized and unissued shares.
Cue Biopharma, Inc. reported first-quarter 2026 results showing sharply higher collaboration revenue and a smaller loss, while still facing going concern risks. Collaboration revenue rose to $5.7 million from $0.4 million a year earlier, driven mainly by its partnership with Boehringer Ingelheim for B‑cell depletion programs.
The company’s net loss narrowed to $5.2 million, compared with $12.3 million in the prior-year quarter, helped by lower research and development spending. Cash, cash equivalents and restricted cash were $16.5 million as of March 31 2026, after using $10.9 million in operating cash during the quarter.
Management states that accumulated deficits, ongoing losses and limited cash raise substantial doubt about the ability to continue as a going concern, though it highlights an April 2026 1‑for‑30 reverse stock split, at‑the‑market share sales, and a $27.6 million May 2026 private placement of pre‑funded and common stock warrants as key capital-raising steps. The pipeline centers on lead antibody CUE‑221 in Phase 2 for allergic diseases and autoimmune candidate CUE‑401 progressing toward Phase 1.
Cue Biopharma reported third‑quarter results, highlighting lower collaboration revenue and continued operating losses, alongside a new collaboration that adds near‑term cash. Collaboration revenue was $2.1 million versus $3.3 million a year ago. Operating expenses totaled $9.7 million, yielding a net loss of $7.4 million (vs. $8.7 million in Q3 2024).
Liquidity remained tight with cash, cash equivalents and marketable securities of $18.7 million as of September 30, 2025, and management disclosed “substantial doubt” about continuing as a going concern. A subsequent Collaboration and License Agreement with ImmunoScape includes upfront payments totaling $15.0 million; approximately $10.0 million is due in Q4 2025 (of which $5.0 million has been received), and $5.0 million before the first anniversary of the effective date. Term loans are due on December 1, 2025. As of November 7, 2025, shares outstanding were 78,737,736.
Cue Biopharma reported continued clinical-stage operating losses while taking steps to bolster liquidity through financing and partnerships. The company held $27.5 million of cash and cash equivalents as of June 30, 2025 and reported a net loss of $20.7 million for the six months ended June 30, 2025 (net loss of $8.48 million for the quarter). Accumulated deficit was $362.6 million and weighted average shares outstanding increased to 84.86 million for the six-month period.
The company raised capital through a 2025 public offering that generated $18.0 million net proceeds, modest ATM proceeds during the period, and received a $10.1 million upfront payment from a collaboration and license agreement with Boehringer Ingelheim (BI) that also includes up to approximately $345 million in potential milestones and royalties. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes all Term Loans are due December 1, 2025.